by McDermott + Bull | Mar 3, 2026 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden, Jake Vander Zanden Article
In every conversation I have with life sciences executives across Southern California, one theme continues to surface. Companies are innovating, hiring, raising capital, and advancing science at an impressive pace. Yet many leaders still feel disconnected from the...
by McDermott + Bull | Nov 13, 2025 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden, Jake Vander Zanden Article
About the Report This report was prepared by SoCalBio to highlight findings from The State of the Bioscience Industry in Greater Los Angeles, presented at the 27th Annual SoCalBio Conference. Medical Devices Lead Regional Strength The Greater Los Angeles bioscience...
by McDermott + Bull | Dec 11, 2024 | Garrett Lipus Article, Article, Garrett Lipus, Healthcare + Life Sciences, Healthcare + Life Sciences Article
After a subdued start to the year, PE healthcare services investing in Q3 2024 showed early signs of a rebound. Despite a modest dip in deal volume from Q2, with 148 deals announced or closed, investor confidence is slowly returning. Much of the activity focused on...
by McDermott + Bull | Nov 27, 2024 | Ken Dropiewski, Article, Healthcare + Life Sciences, Healthcare + Life Sciences Article, Ken Dropiewski Article
What a difference a year makes. In the first half of 2024, the MedTech sector showed a notable uptick in M&A activity, with 114 acquisitions valued at $40.3 billion — close to last year’s total. Despite fewer venture rounds, funding remained strong at $9.7...
by McDermott + Bull | Jun 25, 2024 | Healthcare + Life Sciences, Healthcare + Life Sciences Article, Ken Dropiewski, Ken Dropiewski Article, Technology Article
The JPM Q1 2024 MedTech Licensing and Venture report highlights the first quarter of 2024 and shows promising developments in the MedTech investment landscape. There are indications of a potential recovery and growth compared to previous years. Can we be so lucky?...
by McDermott + Bull | May 22, 2024 | Article, Garrett Lipus, Garrett Lipus Article, Healthcare + Life Sciences, Healthcare + Life Sciences Article, Lipus
Healthcare PE activity in Q1 2024 remained subdued, marking a continuation of the downturn seen in 2023. PE sponsors announced or closed an estimated 158 deals in the quarter, maintaining the sluggish pace of 2023. Despite a somewhat more optimistic narrative around...
